ChemoCentryx, Inc. (CCXI) Reaches $13.50 After 5.00% Down Move; Maryland Capital Management Has Lowered Vulcan Materials Com (VMC) Stake By $1.10 Million

Vulcan Materials Company (NYSE:VMC) Logo

The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) is a huge mover today! The stock decreased 2.81% or $0.39 during the last trading session, reaching $13.5. About 278,035 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 12.22% since April 1, 2018 and is uptrending. It has outperformed by 7.85% the S&P500. Some Historical CCXI News: 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 13/03/2018 – CHEMOCENTRYX INC CCXI.O : JP MORGAN RAISES TARGET PRICE TO $16 FROM $13; 09/03/2018 – ChemoCentryx 4Q Net $39.7M; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 09/03/2018 ChemoCentryx 4Q EPS 80cThe move comes after 7 months negative chart setup for the $709.69 million company. It was reported on Apr, 1 by Barchart.com. We have $12.83 PT which if reached, will make NASDAQ:CCXI worth $35.48M less.

Maryland Capital Management decreased Vulcan Materials Com (VMC) stake by 10.66% reported in 2018Q4 SEC filing. Maryland Capital Management sold 11,206 shares as Vulcan Materials Com (VMC)’s stock rose 6.63%. The Maryland Capital Management holds 93,878 shares with $9.28 million value, down from 105,084 last quarter. Vulcan Materials Com now has $15.88B valuation. The stock increased 1.56% or $1.85 during the last trading session, reaching $120.25. About 800,862 shares traded. Vulcan Materials Company (NYSE:VMC) has declined 1.67% since April 1, 2018 and is downtrending. It has underperformed by 6.04% the S&P500. Some Historical VMC News: 03/05/2018 – VULCAN MATERIALS 1Q ADJ EPS CONT OPS 44C, EST. 23C; 29/03/2018 – REG-DECISIONS OF RAPALA VMC CORPORATION’S ANNUAL GENERAL MEETING ON 29 MARCH 2018; 03/05/2018 – Vulcan Materials 1Q EPS 39c; 19/04/2018 – S&P ASSIGNS LEGACY VULCAN LLC TO RATING ‘BBB’; 03/05/2018 – Vulcan Materials 1Q Rev $854.5M; 17/04/2018 – Vulcan Announces First Quarter Conference Call; 16/03/2018 – VULCAN MATERIALS- ON MARCH 13, UNIT RECEIVED DANGER ORDER ISSUED BY THE MINE SAFETY AND HEALTH ADMINISTRATION AT ITS CALERA QUARRY IN CALERA, ALABAMA; 03/05/2018 – VULCAN MATERIALS CO VMC.N FY2018 SHR VIEW $4.26 — THOMSON REUTERS l/B/E/S; 03/05/2018 – VULCAN MATERIALS CO – FOR 2018, EXPECT ADJUSTED EBITDA OF $1.150 TO $1.250 BLN; 03/05/2018 – Vulcan Materials Sees FY Cont Ops EPS $4.00-EPS $4.65

More recent Vulcan Materials Company (NYSE:VMC) news were published by: Seekingalpha.com which released: “JPMorgan picks up Vulcan, Martin Marietta Materials coverage as a bull – Seeking Alpha” on March 21, 2019. Also Benzinga.com published the news titled: “Benzinga’s Top Upgrades, Downgrades For March 21, 2019 – Benzinga” on March 21, 2019. Seekingalpha.com‘s news article titled: “Vulcan Materials declares $0.31 dividend – Seeking Alpha” with publication date: February 08, 2019 was also an interesting one.

Among 8 analysts covering Vulcan Materials (NYSE:VMC), 6 have Buy rating, 1 Sell and 1 Hold. Therefore 75% are positive. Vulcan Materials had 13 analyst reports since October 11, 2018 according to SRatingsIntel. DA Davidson maintained the stock with “Neutral” rating in Thursday, October 11 report. On Thursday, December 6 the stock rating was upgraded by Nomura to “Buy”. The firm has “Buy” rating by J.P. Morgan given on Thursday, March 21. On Wednesday, October 17 the stock rating was downgraded by Bank of America to “Underperform”. The stock of Vulcan Materials Company (NYSE:VMC) has “Buy” rating given on Friday, January 4 by Citigroup. Citigroup maintained Vulcan Materials Company (NYSE:VMC) rating on Wednesday, October 31. Citigroup has “Buy” rating and $128 target. On Wednesday, March 6 the stock rating was upgraded by Goldman Sachs to “Buy”.

Investors sentiment decreased to 0.91 in Q4 2018. Its down 0.08, from 0.99 in 2018Q3. It turned negative, as 63 investors sold VMC shares while 160 reduced holdings. 71 funds opened positions while 132 raised stakes. 121.80 million shares or 0.80% less from 122.79 million shares in 2018Q3 were reported. Susquehanna Int Group Ltd Liability Partnership has 0% invested in Vulcan Materials Company (NYSE:VMC). First Tru Advisors Limited Partnership has invested 0% in Vulcan Materials Company (NYSE:VMC). 55,361 are owned by Broadview Advsr Lc. Oregon Employees Retirement Fund has invested 0.01% of its portfolio in Vulcan Materials Company (NYSE:VMC). Moreover, Northwestern Mutual Wealth Mgmt has 0% invested in Vulcan Materials Company (NYSE:VMC). 3,347 are held by Bkd Wealth Advsr Llc. Ing Groep Nv invested 0.01% in Vulcan Materials Company (NYSE:VMC). 311 were reported by Walleye Trading Ltd Llc. Invsts has 0.01% invested in Vulcan Materials Company (NYSE:VMC) for 250,000 shares. Art Ltd Liability Corporation holds 22,900 shares. First Republic Invest Management Inc accumulated 4,172 shares. Voloridge Management Limited Co owns 74,596 shares. Raymond James And owns 108,622 shares. 2,775 are held by Cap Innovations Limited Liability Co. The Illinois-based Oakbrook Invs has invested 0.05% in Vulcan Materials Company (NYSE:VMC).

Analysts await Vulcan Materials Company (NYSE:VMC) to report earnings on May, 2. They expect $0.36 EPS, down 18.18% or $0.08 from last year’s $0.44 per share. VMC’s profit will be $47.54M for 83.51 P/E if the $0.36 EPS becomes a reality. After $0.99 actual EPS reported by Vulcan Materials Company for the previous quarter, Wall Street now forecasts -63.64% negative EPS growth.

Maryland Capital Management increased Trex Company Inc (NYSE:TREX) stake by 18,067 shares to 184,577 valued at $10.96 million in 2018Q4. It also upped Vf Corp (NYSE:VFC) stake by 191,600 shares and now owns 194,078 shares. Tableau Software Inc (NYSE:DATA) was raised too.

Among 5 analysts covering ChemoCentryx (NASDAQ:CCXI), 5 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. ChemoCentryx had 5 analyst reports since November 12, 2018 according to SRatingsIntel. H.C. Wainwright maintained ChemoCentryx, Inc. (NASDAQ:CCXI) on Tuesday, March 12 with “Buy” rating. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) has “Buy” rating given on Wednesday, March 27 by FBR Capital. The firm has “Buy” rating given on Thursday, February 14 by Leerink Swann. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) has “Buy” rating given on Monday, November 12 by Canaccord Genuity.

Since October 16, 2018, it had 0 buys, and 8 insider sales for $87.64 million activity. GLAXOSMITHKLINE PLC had sold 7.34 million shares worth $85.85 million on Tuesday, October 16. 7,211 ChemoCentryx, Inc. (NASDAQ:CCXI) shares with value of $86,554 were sold by Schall Thomas J.. Cappel Markus J. had sold 13,203 shares worth $158,790. $457,747 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) shares were sold by KANAYA SUSAN M.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $709.69 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It currently has negative earnings. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Globenewswire.com which released: “ChemoCentryx Appoints Rita Jain, M.D. to Board of Directors – GlobeNewswire” on March 28, 2019, also Nasdaq.com with their article: “ChemoCentryx (CCXI) Looks Good: Stock Adds 5.5% in Session – Nasdaq” published on March 19, 2019, Nasdaq.com published: “ChemoCentryx (CCXI) Reports Q4 Loss, Lags Revenue Estimates – Nasdaq” on March 11, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Nasdaq.com and their article: “After-Hours Earnings Report for March 11, 2019 : ADT, COUP, SFIX, DRNA, AVD, PETQ, CCXI, LXFR, MG, OXFD, FRTA, KALA – Nasdaq” published on March 11, 2019 as well as Benzinga.com‘s news article titled: “60 Stocks Moving In Wednesday’s Mid-Day Session – Benzinga” with publication date: March 27, 2019.

Vulcan Materials Company (NYSE:VMC) Institutional Positions Chart


Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *